
|Articles|November 16, 2012
Direct renin inhibitor adjunct not helpful in T2DM patients at high risk for CV, renal events
Adding aliskiren to standard therapy with renin-angiotensin system blockade could be harmful and did not lower the risk of cardiovascular and renal adverse events when used in patients with type 2 diabetes at risk for these events, according to an online study in the New England Journal of Medicine.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pneumococcal Diseases Require Constant Vaccine Development | NCPA 2025
2
Why Pharmacists Need to Put More Emphasis on Supplement Education | NCPA 2025
3
FDA Approves Oral Semaglutide for Risk of MACE for Patients With Diabetes
4
American Pharmacists Month: Pharmacy Collaboration Enables Delivery of Better Patient Care
5